Cell Signaling Technology

Product Pathways - Protein Stability

UBE2C Antibody #14234

UbcH10   UBE2   UBE2C   Ubiquitin Conjugating Enzymes   Ubiquitination  

No. Size Price
14234S 100 µl ( 10 western blots ) ¥3,100.00 现货查询 购买询价
14234 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
W 1:1000 Human,Mouse,Rat,Monkey, Endogenous 20 Rabbit

Species cross-reactivity is determined by western blot.

Applications Key: W=Western Blotting,

Specificity / Sensitivity

UBE2C Antibody recognizes endogenous levels of total UBE2C protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human UBE2C protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using UBE2C Antibody (upper) and GAPDH (D16H11) XP® Rabbit mAb #5174 (lower).

Western Blotting

Western Blotting

Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a construct expressing Myc/DDK-tagged full-length human UBE2C protein (hUBE2C-Myc/DDK; +), using UBE2C Antibody.


Protein ubiquitination requires the concerted action of the E1, E2, and E3 ubiquitin-conjugating enzymes. Ubiquitin is first activated through ATP-dependent formation of a thiol ester with ubiquitin-activating enzyme E1. The activated ubiquitin is then transferred to a thiol group of ubiquitin-carrier enzyme E2. The final step is the transfer of ubiquitin from E2 to an ε-amino group of the target protein lysine residue, which is mediated by ubiquitin-ligase enzyme E3 (1).

Ubiquitin-conjugating enzyme 2C (UBE2C) is one of several ubiquitin conjugating enzymes participating in the E3 anaphase-promoting complex (APC/C). UBE2C is involved in the control of multiple stages of the cell cycle including inactivation of the mitotic spindle assembly checkpoint (2). UBE2C facilitates ubiquitin-dependent proteasomal degradation by initiating K11-linked ubiquitin chains on APC/C substrates (3). Research studies show that UBE2C expression is low in normal tissues, but its expression is dramatically upregulated in tumors derived from tissues such as lung, breast, and prostate (3-8). Overexpression of UBE2C in many types of solid tumors has been attributed to genomic amplification of the UBE2C locus and research studies have suggested that inhibition of UBE2C activity may have therapeutic potential (9).

  1. Hershko, A. (1988) J Biol Chem 263, 15237-40.
  2. Reddy, S.K. et al. (2007) Nature 446, 921-5.
  3. Wickliffe, K.E. et al. (2011) Cell 144, 769-81.
  4. Okamoto, Y. et al. (2003) Cancer Res 63, 4167-73.
  5. Berlingieri, M.T. et al. (2007) Eur J Cancer 43, 2729-35.
  6. Loussouarn, D. et al. (2009) Br J Cancer 101, 166-73.
  7. Wang, Q. et al. (2009) Cell 138, 245-56.
  8. Chen, Z. et al. (2011) EMBO J 30, 2405-19.
  9. Wagner, K.W. et al. (2004) Oncogene 23, 6621-9.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

XP is a registered trademark of Cell Signaling Technology, Inc.

Tween is a registered trademark of ICI Americas, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :